---
title: Oral Nirmatrelvir-Ritonavir as Postexposure Prophylaxis for Covid-19
date: '2024-07-17'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39018532/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20240718181716&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: In this placebo-controlled trial, postexposure prophylaxis
  with nirmatrelvir-ritonavir for 5 or 10 days did not significantly reduce the risk
  of symptomatic SARS-CoV-2 infection. (Funded by Pfizer; ClinicalTrials.gov number,
  ...'
disable_comments: true
---
CONCLUSIONS: In this placebo-controlled trial, postexposure prophylaxis with nirmatrelvir-ritonavir for 5 or 10 days did not significantly reduce the risk of symptomatic SARS-CoV-2 infection. (Funded by Pfizer; ClinicalTrials.gov number, ...